Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Increasing Single Oral Doses of BAY1830839 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs BAY 1830839 (Primary)
- Indications Diffuse large B cell lymphoma; Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2019 Planned End Date changed from 31 Jul 2019 to 5 Aug 2019.
- 26 Jun 2019 Planned End Date changed from 5 Jun 2019 to 31 Jul 2019.